Background: nasopharyngeal carcinoma (NPC) is a complex disease entity that mainly predominates in endemic regions. Real-world data with immunotherapy from nonendemic regions are limited.
Methods: we collected data from patients with recurrent/metastatic (R/M) NPC treated at a center in Greece and 8 centers in Italy. Between 2016 and 2021, 46 patients who were treated with at least one cycle of immune checkpoint inhibitors (ICI) were identified. Herein, we present our results and a review of the literature.
Results: assessment of response was available in 42 patients. Overall, 11 patients responded to immunotherapy (Overall Response Rate-ORR 26.2%). Three patients had complete response (CR), and 8 patients had partial response (PR). Disease control rate (DCR) was 61.9%. Median Progression Free Survival (PFS) was 5.6 months and median Overall Survival (OS) was 19.1 months. Responders to ICI improved PFS and OS as compared to that of nonresponders. A lower probability of responding to ICI was shown in patients with more than three metastatic sites ( = 0.073), metastatic disease at initial diagnosis, ( = 0.039) or EBV DNA positive before ICI initiation, ( = 0.074). Decline in EBV DNA levels was found to be statistically significant associated with best response to ICI ( = 0.049). Safety was manageable.
Conclusions: among 46 patients with R/M NPC treated with immunotherapy in two nonendemic regions, ORR was 26.2% and durable responses were observed. Low disease burden could serve as a biomarker for response to ICI.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750043 | PMC |
| http://dx.doi.org/10.3390/cells11010032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Canadian Perspective on Systemic Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma.
Curr Oncol
January 2025
Department of Medical Oncology, Arthur JE Child Comprehensive Centre, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 5G2, Canada.
Although the majority of patients with nasopharyngeal carcinoma (NPC) present with early-stage or locoregional disease that can be treated with definitive radiotherapy, approximately 20% of patients experience disease recurrence, and 15% present with metastatic disease that is not amenable to curative therapy. Management of patients with recurrent or metastatic (r/m) NPC who are not candidates for local salvage therapy is challenging in Canada, as there is uncertainty in extrapolating evidence that is largely generated from Southeast China to non-endemic regions such as Canada. Currently, treatment options in Canada are limited to chemotherapy regimens that can only achieve short-term response and prolongation of survival.
View Article and Find Full Text PDFChallenges in Global Distribution and Equitable Access to Monkeypox Vaccines.
Viruses
November 2024
Seventh-Day Adventist College of Nursing, Ile-Ife 220103, Nigeria.
The monkeypox outbreak has grown beyond the regions in which it was considered endemic. It has spread from central and west Africa to non-endemic regions like Europe, America, and other parts of the world. It has recently been classified as a public health emergency of international concern.
View Article and Find Full Text PDFA retrospective chart review and thematic analysis of patients seeking mpox vaccination during the initial outbreak in 2022-2023: evaluation of access, motivations, and stigma.
BMC Public Health
December 2024
School of Nursing, Health, York University, Rm. 329A, Health, Nursing and Environmental Studies Building, 104 Scholars Walk, Toronto, M3J 1P3, Canada.
Background: Mpox was identified in many previously non-endemic countries, including Canada, as of May 2022. In response to the increase in cases in Canada, and more specifically the province of Ontario, the vaccine Imvamune was rolled out. Eligibility was governed by provincial health authorities, and the response varied by region.
View Article and Find Full Text PDFDifferent immunogens and prime-boost vaccination strategies affect the efficacy of recombinant candidate vaccines against pathogenic orthopoxviruses.
Virol J
November 2024
Faculty of Pharmacy, Catholic University "Our Lady of Good Counsel", Rr. Dritan Hoxha, 123, Tirana, Albania.
Although not as lethal as variola virus (VARV), the cause of smallpox, monkeypox virus (MPXV) represents a threat to public health, with important infection rates and mortality in several African countries and signs of spreading worldwide. MPXV may establish new reservoirs in non-endemic countries and can be considered a possible biological weapon. Human-to-human MPXV transmission is increasing with a growing susceptibility, coincident with the declining herd immunity against smallpox.
View Article and Find Full Text PDFMVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settings.
Vaccine
December 2024
Bavarian Nordic, Inc., Morrisville, North Carolina, United States of America.
Background: Mpox is a disease endemic to Central and West Africa. It caused outbreaks in non-endemic countries, mainly in 2022. The endemic Democratic Republic of Congo is currently experiencing its largest outbreak yet.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!